LOS ANGELES, CA--(Marketwire - Feb 27, 2012) - In an exclusive video interview with BioMedReports', Richard T. Schumacher, the founder and Chief Executive Officer of Pressure BioSciences Inc. (NASDAQ: [ PBIO ]), tells investors about his firm, their science and the building momentum that has seen interest and volume in the stock rising in recent months.

The life sciences company is ramping up the commercialization of their Pressure Cycling Technology (PCT), which offers the potential for broad applications in a number of established and emerging fields, including genomics, proteomics, drug discovery & development, process purification, pathogen inactivation, immunodiagnostics, and DNA sequencing.

The new video interview with Mr. Schumacher is now available at:

[ http://www.biomedreports.com/2012022790166/video-ceo-of-pressure-biosciences-sees-firms-momentum-continuing-to-build-in-2012.html ]

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

[ http://biomedreports.com/fdacal.html ]

News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com.